Review

Prognostic utility of \textit{BRAF} mutation in papillary thyroid cancer

Mingzhao Xing\textsuperscript{*}

Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287, United States

\textbf{A R T I C L E   I N F O}

\textbf{Article history:}
Received 30 June 2009
Received in revised form 18 September 2009
Accepted 21 October 2009

\textbf{Keywords:}
\textit{BRAF} mutation
Papillary thyroid cancer
Risk stratification
Prognosis
Molecular marker

\textbf{A B S T R A C T}

Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic \textit{T1799A BRAF} mutation. As a novel prognostic molecular marker, this mutation has received considerable attention in recent years for its potential utility in the risk stratification and management of PTC. In PTC, \textit{BRAF} mutation is closely associated with extrathyroidal extension, lymph node metastasis, advanced tumor stages, disease recurrence, and even patient mortality. Many of the responsible molecular derangements promoted by, or associated with, \textit{BRAF} mutation have been identified, including over-expression of tumor-promoting genes, suppression of tumor-suppressor genes, and silencing of thyroid iodide-handling genes, resulting in impairment or loss of radiiodine avidity and hence the failure of radiiodine treatment of PTC. \textit{BRAF} mutation can be readily tested on thyroid fine needle aspiration biopsy specimens, with high preoperative predictive probabilities for clinicopathological outcomes of PTC. As such, the knowledge of \textit{BRAF} mutation status can facilitate more accurate risk stratification and better decision making at various steps in the management of PTC, from preoperative planning of initial surgical scale to postoperative decisions about appropriate radiiodine treatment and thyroid-stimulating hormone suppression, and to selections of appropriate surveillance modalities for PTC recurrence. The greatest utility of \textit{BRAF} mutation status is in those cases where traditional clinicopathological criteria alone would otherwise be unreliable in the risk stratification and management of PTC. Use of this unique molecular marker, in conjunction with conventional clinicopathological risk factors, to assist the prognostication of PTC is likely to improve the efficiency of contemporary management of thyroid cancer.

\textbf{Contents}

1. Introduction ............................................................... 86
2. PTC and its risk management ........................................... 87
3. \textit{BRAF} mutation and aggressive pathological and molecular derangements in PTC .............................................................. 87
4. \textit{BRAF} mutation and poor clinical outcomes of PTC .................................................................................. 88
5. High predictive power of \textit{BRAF} mutation status for the prognosis of PTC ..................................................... 89
6. \textit{BRAF} mutation-assisted decision making on initial surgical management of PTC ................................................. 89
7. \textit{BRAF} mutation-assisted decision making on initial radiiodine treatment of PTC ....................................................... 90
8. \textit{BRAF} mutation-assisted decision making in follow-up of patients with PTC ................................................................. 90
9. Concluding remarks .......................................................... 91

\textbf{A c k n o w l e d g e m e n t}

Conflict of interest .......................................................... 91
Acknowledgement ............................................................ 91
References ............................................................................. 91

\textbf{© 2009 Elsevier Ireland Ltd. All rights reserved.}

1. Introduction

Thyroid cancer is the most common endocrine malignancy and its incidence has seen a rapid global rise in the recent decades (Hundahl et al., 1998; Leenhardt et al., 2004; Davies and Welch, 2006; Sprague et al., 2008; Horner et al., 2009). In the USA, this incidence rise is currently the fastest among all cancers, with an estimated incidence of 37,200 cases and a prevalence of >360,000 cases for the year 2009 (Horner et al., 2009). The vast majority of thyroid cancers originate from follicular epithelial cells, which are histologically classified as papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC). Given
the already large and still rising number of patients with thyroid cancer, vigorous efforts have been made to optimize the strategies for efficiently managing this cancer. The products of these efforts can be seen in the guidelines or consensuses on the management of thyroid cancer published by several organizations or experts in recent years (Cooper et al., 2009; Pacini et al., 2006, 2008; Sundram et al., 2006; Sherman et al., 2007). Such guidance based on evidence or expert opinion has contributed greatly to improving the standardization and efficiency of the management of thyroid cancer. However, there are still controversies in many areas over the optimal management of this cancer. In this context, effort in molecular thyroid cancer medicine has now shown great promises in helping improve the management of thyroid cancer. One of the best examples is the characterization of the T1799A BRAF mutation (termed BRAF mutation hereafter) as a novel and effective prognostic molecular marker (Xing, 2005, 2007), which has now started entering the clinic for the management of PTC.

2. PTC and its risk management

PTC accounts for 80–90% of all thyroid cancers (Hundahl et al., 1998; Leenhardt et al., 2004; Davies and Welch, 2006). The current rise in the incidence of thyroid cancer is virtually solely from an increased incidence of PTC (Leenhardt et al., 2004; Davies and Welch, 2006; Sprague et al., 2008). Consequently, the bulk of the effort in today’s thyroid cancer medicine is dedicated to managing PTC. In the USA and many European countries, the standard treatments for PTC consist of surgical thyroidectomy in virtually all patients, followed by radioiodine ablation in many patients (Cooper et al., 2009; Pacini et al., 2006, 2008; Sherman et al., 2007; Mazzaferri, 2006). The latter treatment takes advantage of the unique radioiodine avidity of thyroid cells through their ability to take up and concentrate iodide as a substrate for thyroid hormone synthesis, a process that requires the normal functioning of several thyroid iodide-handling genes (Nilsson, 2001). Although with these treatments patients with PTC generally have a low mortality, the disease can recur and often progress into an incurable disease that is surgically inoperable and lacks radioiodine avidity. Overall, the recurrence rate of PTC is high, around 20–30% at 15–20 years (Hay et al., 1993; Mazzaferri and Jhiang, 1994; Fonseca et al., 1997; Gilliland et al., 1997). Even in PTC that is regarded as low-risk based on conventional clinicopathological criteria, including papillary thyroid microcarcinoma (PTMC), recurrence is relatively common and even patient death may occasionally occur (Mazzaferri, 2007; Roti et al., 2008). Recurrent PTC is associated with increased morbidity and mortality with significant psychosocial consequences. It has been well documented that a diagnosis of thyroid cancer has a significant impact on the lives of patients (Giusti et al., 2005; Tan et al., 2007; Hoffjizer et al., 2008; Sawka et al., 2009). Recurrent PTC conceivably has a similar significant impact on the lives of patients. Therefore, while trying to reduce the mortality of PTC, an important focus of contemporary thyroid cancer medicine is to effectively prevent and reduce the recurrence of PTC. Appropriately designed initial treatments are the key to preventing the recurrence of PTC while at the same time balancing the risk of treatment-associated adverse effects. After the initial treatments, patients with PTC need to be appropriately followed with various surveillance measures for disease recurrence. In this process, challenges often arise with respect to how aggressive the initial surgical and radioiodine treatments should be and how to optimize the surveillance regimens during subsequent follow-up. Consequently, appropriate risk stratification with efficient prognostication is required to optimize the management of patients with PTC. This is traditionally performed using the conventional risk stratification system based on clinicopathological criteria, including patient age and gender, tumor size, status of extrathyroidal extension and metastasis, and stages of the tumor (Cooper et al., 2009; Pacini et al., 2006, 2008; Sherman et al., 2007; Mazzaferri, 2006). Risk stratification based on this system, however, is often unreliable and incomplete, particularly when dealing with apparently low-risk patients and when making clinical decisions preoperatively when histopathological information is not available. This unreliability is a main cause of some of the major controversies over the optimal management of PTC. It is in this context that the BRAF mutation as a novel and effective prognostic molecular marker, to be reviewed here, has important utility in helping optimize the management of PTC (Xing, 2005, 2007).

3. BRAF mutation and aggressive pathological and molecular derangements in PTC

The BRAF mutation is a common somatic mutation in thyroid cancer, occurring exclusively in about 45% of PTC and 25% of ATC; it does not occur in FTC, medullary thyroid cancer, and benign thyroid tumors (Xing, 2005). By aberrantly and constitutively activating the Ras → Raf → MAP kinase/ERK pathway (MAP kinase pathway), the resultant mutant BRAF V600E kinase is potently oncogenic (Davies et al., 2002). Recent years have seen an explosion of literature on the role of this mutation in the tumorigenesis of PTC (Xing, 2005, 2007; Knauf and Fagin, 2009). Most of these studies, from various ethnic and geographical backgrounds, demonstrated a strong association of BRAF mutation with poor clinicopathological outcomes of PTC. In particular, as reviewed previously (Xing, 2007), many well-designed large studies demonstrated a close association of BRAF mutation with extrathyroidal extension, lymph node metastasis, and advanced TNM stage III/IV of PTC, which are all major clinicopathological risk factors conventionally associated with increased rates of recurrence and mortality of thyroid cancer (Hay et al., 1993; Mazzaferri and Jhiang, 1994; Fonseca et al., 1997; Gilliland et al., 1997). Among the several major subtypes of PTC, BRAF mutation is most commonly associated with the aggressive tall-cell variant of PTC and least commonly with the less aggressive follicular variant of PTC (Xing, 2005, 2007). This relationship between BRAF mutation and poor clinicopathological outcomes of PTC has been widely confirmed in many recent studies (Nakayama et al., 2007; Abubaker et al., 2008; Frasca et al., 2008; Elisei et al., 2008; Henderson et al., 2009; Kim et al., 2009; Oler and Cerutti, 2009). Even in the case of PTMC, BRAF mutation was found to be associated with aggressive pathological outcomes of the tumor, such as extrathyroidal extension, lymph node metastasis, and high TNM stages (Lupi et al., 2007; Rodolico et al., 2007; Frasca et al., 2008; Lee et al., 2009). Interestingly, BRAF mutation in metastatic PTC in lymph nodes was associated with larger size of the metastases and extra-nodal extension (Rodolico et al., 2007). The aggressive pathogenic role of BRAF mutation in human PTC was completely reproduced in transgenic mice in which targeted over-expression or endogenous expression of the mutant BRAF in thyroid glands promoted the development of PTC with extensive invasion and metastasis (Knauf et al., 2005; Malguarnera et al., 2008).

In contrast to BRAF mutation, Ras mutations and RET/PTC rearrangements, which are also common genetic alterations in PTC, were much less commonly associated with either aggressive pathogenesis of PTC in adult patients or relevant molecular derangements (Adeniran et al., 2006; Mitsutake et al., 2005; Giordano et al., 2005; Mesa et al., 2006; Romei et al., 2008), suggesting that although these oncogenes are, like BRAF mutation, conventionally known to be coupled to the MAP kinase pathway, they are likely less potent than BRAF mutation in activating this pathway and promoting the aggressiveness of PTC. This is consistent with the finding in transgenic mice that targeted endogenous
expression of mutant BRAF induced the development of aggressive PTC associated with aberrant silencing of important thyroid genes while a mutant H-Ras did not (Malguarnera et al., 2008). BRAF mutation is uniquely associated with the over-expression of many classical tumor-promoting molecules in PTC. Examples include VEGF (Jo et al., 2006), c-MET (Giordano et al., 2005), matrix metalloproteinase (Frasca et al., 2008; Mesa et al., 2006; Melillo et al., 2005; Palona et al., 2006), nuclear factor kappa B (Palona et al., 2009), and vimentin (Watanabe et al., 2009). Aberrant promoter methylation of several tumor-suppressor and DNA repair genes in association with BRAF mutation was also demonstrated and associated with aggressive pathological characteristics of PTC (Hu et al., 2006; Guan et al., 2008). When the tumor-suppressor gene p27-Kip1 was examined in primary PTC and matched lymph node metastases, its expression was found to be decreased in both specimens in association with BRAF mutation (Rodolico et al., 2007). These serious molecular derangements associated with or promoted by BRAF mutation represent some of the molecular mechanisms underlying the unique role of BRAF mutation in promoting the aggressiveness of PTC.

4. BRAF mutation and poor clinical outcomes of PTC

Consistent with the association of the BRAF mutation with the aggressive pathological and molecular derangements of PTC is the close association of the BRAF mutation with PTC recurrence initially demonstrated in 2005 (Xing et al., 2005). Many subsequent studies from various ethnic and geographical backgrounds from around the world confirmed this finding (Abubaker et al., 2008; Elisei et al., 2008; Kim et al., 2006; Riesco-Eizaguirre et al., 2006; Kebebew et al., 2007; Xing et al., 2009). These studies, with documented follow-up procedures for the patients investigated, widely showed high odds ratios for disease persistence/recurrence of PTC with BRAF mutation (Table 1 and Fig. 1A), thus demonstrating the strong predictive power of BRAF mutation for the recurrence of PTC. Some of these studies also performed multivariate analyses to justify the confounding effects of the conventional clinicopathological factors and demonstrated a strong and incremental predictive power of BRAF mutation for the recurrence of PTC (Elisei et al., 2008; Xing et al., 2005; Kebebew et al., 2007). Interestingly, in one of these studies, it was shown that the predictive power of BRAF mutation for PTC recurrence was even higher in conventionally low-risk patients, such as those with stage I or II disease, than it was in the overall analysis of all PTC patients (Xing et al., 2005). The association of BRAF mutation in primary PTC tumors with disease recurrence is consistent with the recently reported finding of an extremely high prevalence of BRAF mutation, around 80–85%, in recurrent PTC tumors (Nakayama et al., 2007; Henderson et al., 2009). A recent study with a long-term (15-year median) follow-up of patients investigated the role of BRAF mutation in PTC-associated mortality and demonstrated a significant association of BRAF mutation with increased mortality of PTC (Elisei et al., 2008) (Fig. 1B). Interestingly, PTC developed from mutant BRAF in transgenic mice was associated with a high and rapid mortality rate of animals (Knauf et al., 2005).

### Table 1

<table>
<thead>
<tr>
<th>Patient groups</th>
<th>BRAF mutation (+)</th>
<th>BRAF mutation (−)</th>
<th>Clinical follow-up months (median)</th>
<th>Odds ratio (95% CI)</th>
<th>P value</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>American</td>
<td>23/92 (25)</td>
<td>9/96 (9)</td>
<td>15</td>
<td>3.37 (1.47–7.74)</td>
<td>0.006</td>
<td>Xing et al. (2005)</td>
</tr>
<tr>
<td>Korean</td>
<td>32/149 (21)</td>
<td>4/54 (7)</td>
<td>88</td>
<td>3.42 (1.15–10.18)</td>
<td>0.022</td>
<td>Kim et al. (2006)</td>
</tr>
<tr>
<td>Spanish</td>
<td>9/28 (32)</td>
<td>3/39 (8)</td>
<td>36</td>
<td>5.68 (1.37–23.52)</td>
<td>0.021</td>
<td>Riesco-Eizaguirre et al. (2006)</td>
</tr>
<tr>
<td>American</td>
<td>38/111 (34)</td>
<td>18/98 (18)</td>
<td>72</td>
<td>2.31 (1.21–4.41)</td>
<td>0.012</td>
<td>Kebebew et al. (2007)</td>
</tr>
<tr>
<td>Middle Eastern</td>
<td>44/153 (29)</td>
<td>25/143 (18)</td>
<td>66</td>
<td>1.91 (1.09–3.32)</td>
<td>0.027</td>
<td>Abubaker et al. (2008)</td>
</tr>
<tr>
<td>Italian</td>
<td>13/38 (28)</td>
<td>6/64 (9)</td>
<td>180</td>
<td>5.03 (1.72–14.73)</td>
<td>0.003</td>
<td>Elisei et al. (2008)</td>
</tr>
<tr>
<td>American</td>
<td>15/40 (38)</td>
<td>6/60 (10)</td>
<td>24</td>
<td>5.40 (1.87–15.57)</td>
<td>0.002</td>
<td>Xing et al. (2009)</td>
</tr>
<tr>
<td>Overall</td>
<td>174/611 (28)</td>
<td>71/354 (13)</td>
<td>–</td>
<td>2.71 (2.00–3.67)</td>
<td>&lt;0.001</td>
<td>–</td>
</tr>
<tr>
<td>Predictive probabilities</td>
<td>28.5%</td>
<td>87.2%</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

The P values were calculated using Fisher’s exact test. The raw data were provided by Dr. Electron Kebebew and Dr. Khawla S. Al-Kuraya, through a personal communication (Kebebew et al., 2007; Abubaker et al., 2008). The data from Xing et al. (2009) included in this table do not overlap with the data in Xing et al. (2005). This table is updated from Xing (2007).

**Fig. 1.** (A) Association of BRAF mutation with PTC recurrence. Odds ratios for PTC recurrence with BRAF mutation in various studies. The line of odds ratio for Riesco-Eizaguirre et al. (2006) data is truncated at the value of 16. The data from Xing et al. (2009) included here do not overlap with the data in Xing et al. (2005). (B) The association of BRAF mutation with decreased survival probability of PTC patients. B is adapted from Elisei et al. (2008) with permission.
Compared with BRAF mutation-negative cases, recurrent PTC with BRAF mutation required more aggressive treatments, such as surgical re-operation and external beam radiation, and showed a higher rate of incurability (Xing et al., 2005). An important cause is the BRAF mutation-associated loss of radioiodine avidity and consequent failure of PTC to respond to radioiodine ablation therapy (Xing et al., 2005; Riesco-Eizaguirre et al., 2006; Mian et al., 2008). The direct underlying molecular basis is the BRAF mutation-promoted loss of the expression of thyroid iodide-handling genes in PTC, including the genes for sodium/iodide symporter (NIS), thyroid-stimulating hormone (TSH) receptor, thyroglobulin (Tg), and pendrin (Oler and Cerutti, 2009; Romei et al., 2008; Riesco-Eizaguirre et al., 2006; Mian et al., 2008; Durante et al., 2007; Espadinh et al., 2009). In contrast, RET/PTC and Ras mutations had little impact on the expression of thyroid iodide-handling genes in PTC (Giordano et al., 2005; Romei et al., 2008). Silencing of these thyroid genes upon induced expression of the mutant BRAF was also demonstrated in in vitro thyroid cell line studies (Riesco-Eizaguirre et al., 2006; Liu et al., 2007) and in PTC tumors generated in transgenic mice (Knauf et al., 2005; Malguiner et al., 2008). The mutant BRAF also caused defective transportation of the NIS to the cell membrane, resulting in mislocalization of the NIS in the cytoplasm, thus impairing the ability of the thyroid cells to take up radioiodine (Riesco-Eizaguirre et al., 2006). These are some of the important molecular mechanisms underlying BRAF mutation-promoted loss of radioiodine avidity in PTC and, hence, failure of radioiodine treatment and consequent disease recurrence.

5. High predictive power of BRAF mutation status for the prognosis of PTC

Given its strong association with aggressive clinicopathological outcomes and serious molecular derangements in PTC, the BRAF mutation has become a unique and valuable prognostic molecular marker in the management of PTC. As discussed above, it is the disease persistence/recurrence that is practically a primary concern in managing PTC in most patients. Conceivably, when PTC recurs, it represents the existence of cancer, which, in terms of the impact on the life of the patient, is similar to, or perhaps even more profound than, a new diagnosis of thyroid cancer (Giusti et al., 2005; Tan et al., 2007; Hofijzer et al., 2008; Sawka et al., 2009). Based on the overall data in Table 1, the positive and negative predictive probabilities for BRAF mutation to predict the recurrence of PTC are 28% and 87%, respectively. This positive probability of BRAF mutation to predict PTC recurrence is, in a practical sense, a significant one. In terms of the significance and potential consequence of cancer risk, this may be better appreciated if one considers the case of cytologically “indeterminate” thyroid nodules which are associated with a probability of about 15–20% for malignancy and are thus virtually always recommended for thyroidectomy (Cooper et al., 2009; Gharib and Papini, 2007). Another analogous case to consider is general thyroid nodules that have a probability of about 5% for malignancy, but, even with this much lower probability, invasive fine needle aspiration biopsy (FNAB) is currently recommended for most patients with thyroid nodules of a size (e.g., >1.0 cm) suitable for biopsy (Cooper et al., 2009; Gharib and Papini, 2007). Therefore, a positive predictive probability of around 30% for BRAF mutation to predict PTC recurrence is highly relevant clinically. Similarly, a high negative predictive value of around 90% to exclude PTC recurrence is also highly relevant clinically. As will be discussed in the following sections, given these high predictive powers, BRAF mutation status may have a place particularly in some challenging areas related to optimization of the management of PTC.

6. BRAF mutation-assisted decision making on initial surgical management of PTC

A major, and perhaps the most commonly encountered, challenge related to initial surgical decision making for PTC is the often preoperative uncertainty about the appropriate surgical extent for a particular patient (Witt, 2008). For example, it is often not straightforward to decide whether total thyroidectomy (as opposed to lobectomy) and neck dissection (as opposed to no neck dissection) should be pursued. Such surgical extents are generally associated with significantly decreased recurrence and mortality rates but also pose increased risk for surgical complications, such as injuries to the recurrent laryngeal nerve and parathyroid glands (Hay et al., 1987; Scheumann et al., 1994; Sywak et al., 2006; White et al., 2007; Bilimoria et al., 2007). Recurrence of PTC occurs most commonly in the neck lymph nodes, particularly in the central neck compartment, and re-operation of recurrent PTC is associated with an even further increased surgical risk (White et al., 2007; Wilson et al., 1998; Reddy et al., 2006; Schuff et al., 2008). Therefore, in recent years, compartment-based neck dissection, particularly central neck dissection, usually assisted by preoperative neck ultrasonography evaluation and intra-operative examination, has been increasingly performed during the primary surgery for PTC. Preoperative ultrasonography is, however, often insensitive and non-specific in identifying the extrathyroidal extension of the tumor and metastasized lymph nodes in deep locations of the neck, particularly in the central neck (Shimamoto et al., 1998; Kouvarki et al., 2003; Stulak et al., 2006; Ito et al., 2006; Bonnet et al., 2009). Moreover, preoperative ultrasonography has no documented role in predicting the clinical outcomes of PTC, such as recurrence. With intra-operative examination for lymph node metastases, even with careful experienced surgeons, the sensitivity and specificity of this maneuver for identifying metastasized lymph nodes can be poor (Moley and DeBenedetti, 1999). It is therefore often a significant challenge to decide who should receive lymph node dissection, particularly when prophylactically. Given its unique prognostic power discussed above, BRAF mutation may have a special utility in helping minimize this clinical dilemma if it can be tested preoperatively. Indeed, a recent study has provided direct evidence that BRAF mutation detected preoperatively on FNAB specimens predicted well pathological aggressiveness of PTC, such as extrathyroidal extension, lymph node metastasis, advanced TNM stages, and disease recurrence (Xing et al., 2009). In this study, the positive and negative predictive probabilities of BRAF mutation to predict PTC recurrence were tested on preoperative FNAB specimens and shown to be around 30% and 90%, respectively. This is similar to the findings with BRAF mutation analyzed in primary tumors discussed above. Therefore, the use of BRAF mutation can be a novel and useful prognostic strategy to assist preoperative risk stratification and tailored surgical management of PTC.

As recently discussed (Xing, 2009), this BRAF mutation-assisted preoperative prognostication may be particularly useful for the management of conventionally low-risk PTC, such as PTMC or PTC with low TNM stages. It has been consistently shown that a subgroup of such apparently low-risk patients can progress with recurrence or even mortality in some cases, albeit with a lower rate than conventionally high-risk patients (Mazzaferri, 2007; Roti et al., 2008; Pazaitou-Panayiotou et al., 2007). Preoperative BRAF mutation testing may help identify this group of patients for relatively more aggressive initial surgical treatments, such as total thyroidectomy instead of lobectomy. With a positive preoperative BRAF mutation testing, prophylactic central neck dissection in the absence of apparent pathologic lymph nodes may also be favored in a right clinical setting given the highly probable mutant BRAF-driven microscopic lymph node metastasis of PTC which, as discussed above, may be insensitive to radioiodine ablation due to
impaired radioiodine avidity and hence has an increased risk for future recurrence if not removed surgically. On the other hand, given the high negative predictive probability of around 90%, a negative preoperative BRAF mutation test in these patients may greatly favor less aggressive surgery, perhaps sparing prophylactic neck dissection and supporting only lobectomy in an appropriate clinical setting. Even without neck dissection, microscopic PTC metastases in this BRAF mutation-negative group of patients are expected to be highly sensitive to radioiodine and can therefore be effectively cured with radioiodine ablation after thyroidectomy. This BRAF mutation-assisted approach for preoperative surgical decision making will likely significantly reduce the recurrence rate of PTC since compartment-based removal of neck lymph nodes in appropriate patients is effective in preventing the recurrence of PTC. At the same time, this approach will likely also reduce surgical complications since fewer patients would need to be aggressively surgically treated. This is because only about one third of the cases of PTMC or low-stage PTC harbor BRAF mutation (Xing, 2007, 2009) and, in some series, as low as 18–24% of PTMC harbored BRAF mutation (Frasca et al., 2008; Ugolini et al., 2007). Thus, the prevalence of BRAF mutation is much lower in the low-risk PTC patients compared with the overall prevalence of 45% of this mutation in PTC in general and the majority of low-risk patients could consequently be spared from “promiscuous” prophylactic neck dissection. Conventional clinicopathological factors and the technical quality of the surgical service are also important to consider in this BRAF mutation-guided surgical decision making to optimize the balance between the risk of PTC recurrence and the risk of surgical complications.

7. BRAF mutation-assisted decision making on initial radioiodine treatment of PTC

Radioiodine ablation following total or near-total thyroidectomy is a standard medical treatment for PTC in many patients in the USA and many other countries (Cooper et al., 2009; Pacini et al., 2006, 2008; Sherman et al., 2007; Mazzaferri, 2006). The benefit of radioiodine treatment in preventing recurrence and mortality of thyroid cancer has been generally demonstrated for conventionally high-risk patients but inconsistently in low-risk patients (Chow et al., 2003; Jonklaas et al., 2006; Sawk et al., 2008). Radioiodine treatment may be associated with adverse effects, including the risk of development of a second primary cancer (Rubino et al., 2003; Brown et al., 2008). While the overall therapeutic benefit of radioiodine treatment in the conventionally low-risk patients, is still debatable, it may be helpful to use BRAF mutation status to assist decision making in choosing this treatment. As discussed above, the apparently low-risk initial status of a subgroup of PTC patients can give way to aggressive progression with recurrence and even mortality. Since patients who fall into this group usually harbor BRAF mutation, use of BRAF mutation may well help identify them for special management, such as radioiodine treatment. This may particularly apply in the case of PTMC. There has been no general agreement on whether and how to treat PTMC with radioiodine (Mazzaferri, 2007; Hay, 2007). This is because, as large meta-analyses showed (Roti et al., 2008; Pazaitou-Panayiotou et al., 2007), it is not possible to reliably discriminate on the basis of clinicopathological criteria between the aggressive and indolent cases of PTMC. Given the strong association of BRAF mutation with poorer clinicopathological outcomes in PTMC or low-stage PTC (Frasca et al., 2008; Lupi et al., 2007; Rodolico et al., 2007; Lee et al., 2009; Xing et al., 2005), it is reasonable to propose that at least BRAF mutation-positive PTMC be considered for radioiodine treatment. Since this group of patients accounts for the minority of the low-risk patients, it is practically feasible to treat them. Although whether radioiodine treatment can reduce disease recurrence in these patients may need studies to directly test, at this time it may be at least advisable not to spare this group of patients from radioiodine treatment given the known aggressive role of BRAF mutation. Moreover, radioiodine ablation of residual thyroid tissues will improve the specificity of surveillance testing for recurrence using serum thyroglobulin and radioiodine body scan that is likely to be more commonly needed for these BRAF mutation-positive patients who may require a more vigilant follow-up surveillance for their increased risk of recurrence.

Given the impairment of radioiodine avidity with BRAF mutation, a relatively high dose of radioiodine, perhaps 75 mCi or higher, may be reasonable for the conventionally apparently low-risk but BRAF mutation-positive patients. For the conventionally low-risk and BRAF mutation-negative patients, there are not enough data at this time to support the use of BRAF mutation status in deciding whether to treat them with radioiodine. For this group of patients, it is advisable that radioiodine treatment continues to be guided by the conventional risk factors as done in current practice, with perhaps a higher threshold in initiating the treatment in a right clinical setting. If radioiodine treatment is determined to be the option for these patients, it may be reasonable to use a relatively low dose of radioiodine, perhaps 30 mCi, since BRAF mutation-negative PTC in these patients is expected to be highly sensitive to radioiodine ablation and this dose is generally effective and safe in ablating residual normal and cancerous thyroid tissues in low-risk patients.

For PTC patients with conventionally high risk, such as stage III or IV disease, BRAF mutation status may not have a significant role at this time in altering the current approach of determining the need for radioiodine treatment as its benefit in reducing PTC recurrence and mortality in these patients has been well demonstrated (Chow et al., 2003; Jonklaas et al., 2006). However, it remains to be investigated whether BRAF mutation-positive and -negative patients in this high-risk group benefit differentially from radioiodine treatment and whether different doses of radioiodine should be administered to them since BRAF mutation status affects radioiodine sensitivity. The answer to this important question will help optimize the balance between the benefits and harm of radioiodine treatment. Empirically, perhaps a dose of 100 mCi can be generally considered for BRAF mutation-negative cases and a dose of 150 mCi or higher for BRAF mutation-positive cases in this conventionally high-risk group of PTC patients.

8. BRAF mutation-assisted decision making in follow-up of patients with PTC

After the initial surgical and radioiodine treatments, patients with PTC are routinely clinically observed and managed with various standard procedures. Among these, TSH suppression therapy is commonly used as an effort to reduce recurrence and mortality rates (Cooper et al., 2009; Pacini et al., 2006, 2008; Sherman et al., 2007; Mazzaferri, 2006). Like radioiodine therapy for thyroid cancer, the benefit of this practice has been generally shown in high-risk patients but is inconclusive in low-risk patients (Chow et al., 2003; Cooper et al., 1998; McGriff et al., 2002). Low TSH level is achieved by administering a supraphysiologic dose of thyroxine to the patient. It is a general practice to maintain a degree of TSH suppression commensurate with the risk level of the disease in a specific patient. For example, as per the 2009 American Thyroid Association guidelines (Cooper et al., 2009), TSH should be generally maintained at undetectable levels for high-risk patients and subnormal range for low-risk patients. The intent of this approach is to optimize the balance between the benefit of improving clinical outcomes of thyroid cancer and minimizing the adverse effects.
of iatrogenic hyperthyroidism. In this approach, the inherent deficiency of the clinicopathological criteria used in risk stratification, as discussed above, can be problematic, particularly in apparently low-risk patients. Here again, given the BRAF mutation as a strong risk factor for aggressiveness and progression of PTC, even in conventionally low-risk patients, use of BRAF mutation status may help to more appropriately target the TSH levels. For instance, one consideration could be that, for PTMC or low-risk PTC, BRAF mutation-negative patients be generally maintained at TSH levels in the low normal range and BRAF mutation-positive patients be generally maintained at TSH levels in low subnormal ranges. The TSH level in high-risk patients, such as those with stage III or IV disease, may be targeted at the undetectable level regardless of the BRAF mutation status as conventionally recommended until further studies become available.

The level of surveillance for PTC recurrence during clinical follow-up in the current practice may also be tailored based on the BRAF mutation status. Principally, BRAF mutation-positive patients may generally need to be more frequently followed and more vigilantly surveyed, with a lower threshold, for instance, in choosing to use testing modalities, such as TSH-stimulated serum Tg testing, radioiodine body scan, and positron emission tomography (PET) scan. Given the high rate of loss of radioiodine avidity in recurrent PTC with BRAF mutation, it may be reasonable to weigh more heavily toward PET scans than toward radioiodine body scans in deciding the diagnostic imaging modalities in a BRAF mutation-positive patient in a right clinical setting. In contrast, in a BRAF mutation-negative PTC patient, after the initial total thyroidectomy and radioiodine ablation, less aggressive testing modalities can be generally pursued. For example, neck ultrasonography and TSH-stimulated serum Tg testing, or perhaps just Tg testing alone, may be sufficient for most patients and negative results of these tests can be more reliably used to demonstrate a cure for the disease. Again, it should be noted that BRAF mutation may have the best prognostic utility in the management of PTC when applied in conjunction with the use of conventional clinicopathological risk factors.

9. Concluding remarks

Compelling data are now available that demonstrate the high and specific predictive power of BRAF mutation in PTC. This is well supported by its strong predictive value for the pathological aggressiveness, recurrence, and even mortality of PTC. There are well-documented molecular bases to support the unique aggressive role of BRAF mutation in PTC tumorigenesis and hence its prognostic value, including the mutation-promoted over-expression of tumour-promoting molecules, suppression of tumour-suppressor genes, and silencing of iodide-handling genes with impaired radioiodine avidity in PTC. The prognostic value of BRAF mutation may have great utility in many clinical areas of PTC, such as tailoring appropriate surgical and radioiodine treatments, particularly for conventionally low-risk patients, and determining appropriate management during patient follow-up. The ability to use BRAF mutation testing on thyroid FNA specimens to preoperatively predict clinicopathological outcomes of PTC makes it possible and ideal to use this molecular marker at an early stage to assist decision making for PTC. Although specific indications and strategies using BRAF mutation for the management of PTC need to be defined, it is expected that the prognostic use of this remarkable molecular marker will add a new and effective dimension to the current risk stratification system of PTC and, hence, may have a significant impact on the practice of contemporary thyroid cancer medicine.

Conflict of interest

None.

Acknowledgement

This work is supported by NIH grant R01-CA113507 to the author.

References


Cooper, D.S., Specker, B., Ho, M., et al., 1998. Thyrotopin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8, 737–744.


Fronzoni, A., Dima, M., D’Agostino, M., et al., 2009. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 19, 247–255.


Jonklaas, J., Sarlis, N.J., Litsky, D., et al., 2006. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16, 1229–1242.


